RxDoctor Payments Data

Whitney Walker

Psychiatric/Mental Health · Oakland Park, FLNPI 1477068476

Payments from drug & device makers

$2,582in general payments, 2019–2025

Across 144 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$757
  • Otsuka America Pharmaceutical, Inc.$559
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$469
  • Teva Pharmaceuticals USA, Inc.$240
  • Johnson & Johnson$224
  • Alkermes, Inc.$210
  • plus $123 from 4 others

What the payments were for

  • Food & beverage$2,48896%
  • Education$944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,582 in reported general payments places this provider in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$9,626
Medicare patients
55
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate76$207,625
AustedoDeutetrabenazine21$157,377
IngrezzaValbenazine Tosylate11$100,538
Abilify MaintenaAripiprazole28$83,052
VraylarCariprazine Hcl40$60,058
CaplytaLumateperone Tosylate11$20,821
TrintellixVortioxetine Hydrobromide24$11,785
Aripiprazole175$10,054
Quetiapine Fumarate452$7,050
Atomoxetine Hcl24$4,394
Oxcarbazepine106$4,280
Risperidone216$3,913
Quetiapine Fumarate ErQuetiapine Fumarate26$3,867
Lurasidone Hcl17$3,328
Haloperidol106$3,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$224$207,62576 claims
Teva Pharmaceuticals USA, Inc.Austedo$240$157,37721 claims
Neurocrine Biosciences, Inc.Ingrezza$62$100,53811 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$559$83,05228 claims
AbbVieVraylar$757$60,05840 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$469$20,82111 claims
Almatica Pharma LLCSertraline Hcl$16$1,710198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Oakland Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →